This study is for people with advanced non-small cell lung cancer (NSCLC) with extra copies of the MET gene in their tumor. The drug being tested is called amivantamab-vmjw. It aims to stop the cancer from growing or spreading by targeting these extra gene copies. Participants will receive amivantamab through an IV (a method of delivering medicine directly into a vein) over several weeks and will have regular CT or MRI scans to check progress. After finishing the treatment, participants will be followed up for up to 3 years.

Key Points to Consider:

• The study involves receiving medicine via IV and regular scans for progress.
• Participants must meet specific medical criteria, including previously trying other treatments.
• After treatment, follow-up will continue for up to three years.

Participants must have measurable disease, confirmed diagnosis of NSCLC with MET amplification, and meet other health criteria. This trial is investigational, meaning it's still being tested, so participants must sign a consent form acknowledging this. If you fit the criteria and agree to join, you'll help researchers learn more about treating this type of cancer.